Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.71 |
| ▸ | CTSD | P07339 | 9/20 | 0.71 |
| ▸ | CTSE | P14091 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531265 | 0.92 | BACE1 (0.63) | BACE1CTSDCTSE | |
| SCHEMBL2529079 | 0.85 | BACE1 (0.55) | BACE1CTSDCTSE | |
| SCHEMBL2529797 | 0.84 | BACE1 (0.64) | BACE1CTSDCTSE | |
| SCHEMBL2531242 | 0.84 | BACE1 (0.67) | BACE1CTSDCTSE | |
| SCHEMBL2534353 | 0.84 | BACE1 (0.63) | BACE1CTSDCTSE | |
| SCHEMBL2530955 | 0.83 | BACE1 (1.00) | BACE1CTSDCTSE | |
| SCHEMBL2525909 | 0.83 | BACE1 (0.80) | BACE1CTSDCTSE | |
| SCHEMBL2530306 | 0.82 | BACE1 (0.70) | BACE1CTSDCTSE | |
| SCHEMBL2531586 | 0.81 | BACE1 (0.49) | BACE1CTSDCTSE | |
| SCHEMBL2530320 | 0.81 | BACE1 (0.51) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | claimed |
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | BACE1 2477/4885CTSD 557/4885CTSE 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.